Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
在ASCEMBL研究中，经过近4年的随访，阿西米尼在晚期慢性粒细胞白血病慢性期（CML-CP）治疗中仍优于博舒替尼。
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2025016042
Mauro, Michael J; Minami, Yosuke; Hochhaus, Andreas; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong-Wook; Apperley, Jane F; Cortes, Jorge E; Abdo, Andre; Fogliatto, Laura Maria; Kim, Dennis Dong Hwan; le Coutre, Philipp; Saussele, Susanne; Annunziata, Mario; Hughes, Timothy P; Chaudhri, Naeem; Chee, Lynette; García-Gutiérrez, Valentin; Sasaki, Koji; Boquimpani, Carla; Kapoor, Shruti; Espurz, Noemi; Dhamal, Vishal; Rea, Delphine
